Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Amarin Gets Underweight Rating from JPMorgan Chase & Co.

Guavy AI Editorial Team
Instruments
JPM
Share

JPMorgan Chase & Co. has begun coverage on Amarin (NASDAQ:AMRN), assigning an 'underweight' rating and a price target of $13.00 to the biopharmaceutical company's stock.

The firm's target indicates a potential downside of 8.00% from Amarin's previous close.

This is not the only recent analyst action on the stock; Weiss Ratings has reissued a 'sell (d-)' rating, while Zacks Research downgraded Amarin from a 'strong-buy' to a 'hold' rating and Wall Street Zen lowered its rating from 'buy' to 'hold.'

More on Stocks

Stocks just now

Amgen Price Surge Raises Valuation Questions Amid Analyst Target Hikes

Stocks 1m ago

Honeywell UK Workers Ballot for Strike Over Pension Cuts

Stocks 1m ago

Honeywell Workers on Teesside Vote on Strike Action Over Pension Cuts

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy